Development of novel microRNA-based therapy against KRAS/BRAF-mutant colorectal cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462057
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Okayama University
• Principal Investigator: TAZAWA HIROSHI 岡山大学, 大学病院, 助教 (90415513)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: マイクロRNA / 大腸癌 / KRAS / BRAF / EGFR

Outline of Final Research Achievements

KRAS/BRAF-mutant colorectal cancer is an intractable disease that frequently shows the refractory to chemotherapy, recurrence and metastatic progression. Since EGFR signaling pathway is constitutively activated in KRAS/BRAF-mutant colorectal cancer, the development of novel therapy for strongly suppressing EGFR signaling pathway is important issue. Here we show that oncolytic adenoviruses have profound antitumor effect through activation of EGFR-suppressive microRNA and induction of apoptosis- and autophagy-related cell death against KRAS/BRAF-mutant colorectal cancer.

Free Research Field

分子腫瘍学、遺伝子治療学